Exploring Residual Concentrations of Agents in Head and Neck Cancer

Joseph Ciccolini, PhD
Published: Monday, Apr 10, 2017



Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses investigating the residual concentrations of other agents for the treatment of patients with head and neck cancer.

Aside from cetuximab (Erbitux), researchers are working on this novel method with bevacizumab (Avastin). However, the clinical outcomes with this agent are not yet available.

Furthermore, he adds, agents including nivolumab (Opdivo), pembrolizumab (Keytruda), and ipilimumab (Yervoy) are being investigated for residual concentrations. This is because these drugs are effective, but they could be improved and show activity in more patients with different doses or scheduling, Ciccolini explains.


Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses investigating the residual concentrations of other agents for the treatment of patients with head and neck cancer.

Aside from cetuximab (Erbitux), researchers are working on this novel method with bevacizumab (Avastin). However, the clinical outcomes with this agent are not yet available.

Furthermore, he adds, agents including nivolumab (Opdivo), pembrolizumab (Keytruda), and ipilimumab (Yervoy) are being investigated for residual concentrations. This is because these drugs are effective, but they could be improved and show activity in more patients with different doses or scheduling, Ciccolini explains.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x